Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders

Pharmacology and Therapeutics

Volumn 172, Issue , 2017, Pages 22-33

  Hasegawa, Masato ^a   Nonaka, Takashi ^a   Masuda Suzukake, Masami ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

ALS; Alzheimer's disease; Parkinson's disease; Tau; TDP 43; synuclein

Indexed keywords

ALPHA SYNUCLEIN; CELL PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; DNA BINDING PROTEIN; PRION; TDP-43 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DISEASE COURSE; GLIA CELL; HUMAN; MOLECULAR THERAPY; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; ANIMAL; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PRIONS; TAU PROTEINS;

EID: 85008311655     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.11.010     Document Type: Review

References (163)

1. Abounit, S., Bousset, L., Loria, F., Zhu, S., de Chaumont, F., Pieri, L.,.. Zurzolo, C., Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes. The EMBO Journal, 2016.
2. Aguzzi, A., Cell biology. Prion toxicity: All sail and no anchor. Sciences 308 (2005), 1420–1421.
3. Ahmed, Z., Cooper, J., Murray, T.K., Garn, K., McNaughton, E., Clarke, H.,.. O'Neill, M.J., A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta Neuropathologica 127 (2014), 667–683.
4. Aoyagi, H., Hasegawa, M., Tamaoka, A., Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau. The Journal of Biological Chemistry 282 (2007), 20309–20318.
5. Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H.,.. Oda, T., TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications 351 (2006), 602–611.
6. Arai, T., Ikeda, K., Akiyama, H., Nonaka, T., Hasegawa, M., Ishiguro, K.,.. Mochizuki, A., Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Annals of Neurology 55 (2004), 72–79.
7. Asuni, A.A., Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. The Journal of Neuroscience 27 (2007), 9115–9129.
8. Ayala, Y.M., De Conti, L., Avendano-Vazquez, S.E., Dhir, A., Romano, M., D'Ambrogio, A.,.. Baralle, F.E., TDP-43 regulates its mRNA levels through a negative feedback loop. The EMBO Journal 30 (2011), 277–288.
9. Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M.,.. Iwatsubo, T., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. The American Journal of Pathology 152 (1998), 879–884.
10. Bernis, M.E., Babila, J.T., Breid, S., Wusten, K.A., Wullner, U., Tamguney, G., Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathologica Communications, 3, 2015, 75.
11. Berriman, J., Serpell, L.C., Oberg, K.A., Fink, A.L., Goedert, M., Crowther, R.A., Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proceedings of the National Academy of Sciences of the United States of America 100 (2003), 9034–9038.
12. Bigio, E.H., Wu, J.Y., Deng, H.X., Bit-Ivan, E.N., Mao, Q., Ganti, R.,.. Mesulam, M., Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathologica 125 (2013), 463–465.
13. Boudreau, R.L., Rodriguez-Lebron, E., Davidson, B.L., RNAi medicine for the brain: Progresses and challenges. Human Molecular Genetics 20 (2011), R21–R27.
14. Boyd, J.D., Lee-Armandt, J.P., Feiler, M.S., Zaarur, N., Liu, M., Kraemer, B.,.. Glicksman, M.A., A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. Journal of Biomolecular Screening 19 (2014), 44–56.
15. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 82 (1991), 239–259.
16. Braak, H., Del Tredici, K., The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathologica 121 (2011), 171–181.
17. Braak, H., Del Tredici, K., Amyloid-beta may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer's disease: A hypothesis. Acta Neuropathologica 126 (2013), 303–306.
18. Braak, H., Del Tredici, K., Are cases with tau pathology occurring in the absence of Abeta deposits part of the AD-related pathological process?. Acta Neuropathologica 128 (2014), 767–772.
19. Braak, H., Brettschneider, J., Ludolph, A.C., Lee, V.M., Trojanowski, J.Q., Del Tredici, K., Amyotrophic lateral sclerosis–a model of corticofugal axonal spread. Nature Reviews. Neurology 9 (2013), 708–714.
20. Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 24 (2003), 197–211.
21. Brettschneider, J., Del Tredici, K., Irwin, D.J., Grossman, M., Robinson, J.L., Toledo, J.B.,.. Trojanowski, J.Q., Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathologica 127 (2014), 423–439.
22. Brettschneider, J., Del Tredici, K., Lee, V.M., Trojanowski, J.Q., Spreading of pathology in neurodegenerative diseases: A focus on human studies. Nature Reviews. Neuroscience 16 (2015), 109–120.
23. Brettschneider, J., Del Tredici, K., Toledo, J.B., Robinson, J.L., Irwin, D.J., Grossman, M.,.. Trojanowski, J.Q., Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Annals of Neurology 74 (2013), 20–38.
24. Brion, J.P., Flament-Durand, J., Dustin, P., Alzheimer's disease and tau proteins. Lancet, 2, 1986, 1098.
25. Brunden, K.R., Ballatore, C., Lee, V.M., Smith, A.B. 3rd, Trojanowski, J.Q., Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochemical Society Transactions 40 (2012), 661–666.
26. Brundin, P., Melki, R., Kopito, R., Prion-like transmission of protein aggregates in neurodegenerative diseases. Nature Reviews. Molecular Cell Biology 11 (2010), 301–307.
27. Budini, M., Buratti, E., Stuani, C., Guarnaccia, C., Romano, V., De Conti, L., Baralle, F.E., Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. The Journal of Biological Chemistry 287 (2012), 7512–7525.
28. Castillo-Carranza, D.L., Guerrero-Munoz, M.J., Sengupta, U., Hernandez, C., Barrett, A.D., Dineley, K., Kayed, R., Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. The Journal of Neuroscience 35 (2015), 4857–4868.
29. Chesebro, B., Trifilo, M., Race, R., Meade-White, K., Teng, C., LaCasse, R.,.. Oldstone, M., Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308 (2005), 1435–1439.
30. Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R.A., Frank, S., Hench, J.,.. Tolnay, M., Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), 9535–9540.
31. Clavaguera, F., Bolmont, T., Crowther, R.A., Abramowski, D., Frank, S., Probst, A.,.. Tolnay, M., Transmission and spreading of tauopathy in transgenic mouse brain. Nature Cell Biology 11 (2009), 909–913.
32. Clavaguera, F., Hench, J., Lavenir, I., Schweighauser, G., Frank, S., Goedert, M., Tolnay, M., Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathologica 127 (2014), 299–301.
33. Crowther, R.A., Jakes, R., Spillantini, M.G., Goedert, M., Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Letters 436 (1998), 309–312.
34. Dan, A., Takahashi, M., Masuda-Suzukake, M., Kametani, F., Nonaka, T., Kondo, H.,.. Hasegawa, M., Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer's disease brain. Acta Neuropathologica Communications, 1, 2013, 54.
35. Delacourte, A., Defossez, A., Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. Journal of the Neurological Sciences 76 (1986), 173–186.
36. Delaere, P., Duyckaerts, C., Brion, J.P., Poulain, V., Hauw, J.J., Tau, paired helical filaments and amyloid in the neocortex: A morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type. Acta Neuropathologica 77 (1989), 645–653.
37. Doody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S.,.. Semagacestat Study, G, A phase 3 trial of semagacestat for treatment of Alzheimer's disease. The New England Journal of Medicine 369 (2013), 341–350.
38. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S.,.. Solanezumab Study, G, Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. The New England Journal of Medicine 370 (2014), 311–321.
39. El-Agnaf, O.M., Paleologou, K.E., Greer, B., Abogrein, A.M., King, J.E., Salem, S.A.,.. Allsop, D., A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. The FASEB Journal 18 (2004), 1315–1317.
40. Fevrier, B., Vilette, D., Laude, H., Raposo, G., Exosomes: A bubble ride for prions?. Traffic 6 (2005), 10–17.
41. Fontaine, S.N., Zheng, D., Sabbagh, J.J., Martin, M.D., Chaput, D., Darling, A.,.. Dickey, C.A., DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins. The EMBO Journal, 2016.
42. Frost, B., Diamond, M.I., Prion-like mechanisms in neurodegenerative diseases. Nature Reviews. Neuroscience 11 (2010), 155–159.
43. Frost, B., Jacks, R.L., Diamond, M.I., Propagation of tau misfolding from the outside to the inside of a cell. The Journal of Biological Chemistry 284 (2009), 12845–12852.
44. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S.,.. Iwatsubo, T., Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology 4 (2002), 160–164.
45. Goedert, M., NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science, 349, 2015, 1255555.
46. Goedert, M., Jakes, R., Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization. The EMBO Journal 9 (1990), 4225–4230.
47. Goedert, M., Clavaguera, F., Tolnay, M., The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends in Neurosciences 33 (2010), 317–325.
48. Goedert, M., Jakes, R., Crowther, R.A., Hasegawa, M., Smith, M.J., Spillantini, M.G., Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. Biochemical Society Transactions 26 (1998), 463–471.
49. Goedert, M., Jakes, R., Spillantini, M.G., Hasegawa, M., Smith, M.J., Crowther, R.A., Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383 (1996), 550–553.
50. Gousset, K., Zurzolo, C., Tunnelling nanotubes: A highway for prion spreading?. Prion 3 (2009), 94–98.
51. Gousset, K., Schiff, E., Langevin, C., Marijanovic, Z., Caputo, A., Browman, D.T.,.. Zurzolo, C., Prions hijack tunnelling nanotubes for intercellular spread. Nature Cell Biology 11 (2009), 328–336.
52. Greenberg, S.G., Davies, P., A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proceedings of the National Academy of Sciences of the United States of America 87 (1990), 5827–5831.
53. Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M., Binder, L.I., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of the United States of America 83 (1986), 4913–4917.
54. Guo, W., Chen, Y., Zhou, X., Kar, A., Ray, P., Chen, X.,.. Wu, J.Y., An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nature Structural & Molecular Biology 18 (2011), 822–830.
55. Halliday, M., Radford, H., Mallucci, G.R., Prions: Generation and spread versus neurotoxicity. The Journal of Biological Chemistry 289 (2014), 19862–19868.
56. Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., Kudo, Y., Characteristics of tau and its ligands in PET imaging. Biomolecules, 6, 2016, 7.
57. Hasegawa, M., Molecular mechanisms in the pathogenesis of Alzheimer's disease and tauopathies-prion-like seeded aggregation and phosphorylation. Biomolecules, 2016, 6.
58. Hasegawa, M., Arai, T., Akiyama, H., Nonaka, T., Mori, H., Hashimoto, T.,.. Oyanagi, K., TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130 (2007), 1386–1394.
59. Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, Y.,.. Akiyama, H., Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Annals of Neurology 64 (2008), 60–70.
60. Hasegawa, M., Crowther, R.A., Jakes, R., Goedert, M., Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. The Journal of Biological Chemistry 272 (1997), 33118–33124.
61. Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V.M.,.. Iwatsubo, T., Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. The Journal of Biological Chemistry 277 (2002), 49071–49076.
62. Hasegawa, T., Matsuzaki, M., Takeda, A., Kikuchi, A., Akita, H., Perry, G.,.. Itoyama, Y., Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Research 1013 (2004), 51–59.
63. Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., Ihara, Y., Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. The Journal of Biological Chemistry 267 (1992), 17047–17054.
64. Hasegawa, M., Nonaka, T., Tsuji, H., Tamaoka, A., Yamashita, M., Kametani, F.,.. Akiyama, H., Molecular dissection of TDP-43 proteinopathies. Journal of Molecular Neuroscience 45 (2011), 480–485.
65. Hasegawa, M., Watanabe, A., Takio, K., Suzuki, M., Arai, T., Titani, K., Ihara, Y., Characterization of two distinct monoclonal antibodies to paired helical filaments: Further evidence for fetal-type phosphorylation of the tau in paired helical filaments. Journal of Neurochemistry 60 (1993), 2068–2077.
66. Hashimoto, M., Hsu, L.J., Sisk, A., Xia, Y., Takeda, A., Sundsmo, M., Masliah, E., Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Research 799 (1998), 301–306.
67. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A.,.. Nicoll, J.A., Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008), 216–223.
68. Holmes, B.B., DeVos, S.L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K.,.. Diamond, M.I., Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), E3138–E3147.
69. Hurshman, A.R., White, J.T., Powers, E.T., Kelly, J.W., Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43 (2004), 7365–7381.
70. Iba, M., McBride, J.D., Guo, J.L., Zhang, B., Trojanowski, J.Q., Lee, V.M., Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections. Acta Neuropathologica 130 (2015), 349–362.
71. Igaz, L.M., Kwong, L.K., Chen-Plotkin, A., Winton, M.J., Unger, T.L., Xu, Y.,.. Lee, V.M., Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. The Journal of Biological Chemistry 284 (2009), 8516–8524.
72. Inukai, Y., Nonaka, T., Arai, T., Yoshida, M., Hashizume, Y., Beach, T.G.,.. Hasegawa, M., Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Letters 582 (2008), 2899–2904.
73. Jakes, R., Spillantini, M.G., Goedert, M., Identification of two distinct synucleins from human brain. FEBS Letters 345 (1994), 27–32.
74. Jeganathan, S., von Bergen, M., Mandelkow, E.M., Mandelkow, E., The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 47 (2008), 10526–10539.
75. Johnson, R.L., Huang, W., Huang, R., Crowe, A., Ballatore, C., Trojanowski, J.Q.,.. Lee, V.M.Y., High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. 2010, In Probe Reports from the NIH Molecular Libraries Program, Bethesda (MD).
76. Jucker, M., Walker, L.C., Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501 (2013), 45–51.
77. Kametani, F., Obi, T., Shishido, T., Akatsu, H., Murayama, S., Saito, Y.,.. Hasegawa, M., Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Scientific Reports, 6, 2016, 23281.
78. Kassubek, J., Muller, H.P., Del Tredici, K., Brettschneider, J., Pinkhardt, E.H., Lule, D.,.. Ludolph, A.C., Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain 137 (2014), 1733–1740.
79. Konno, M., Hasegawa, T., Baba, T., Miura, E., Sugeno, N., Kikuchi, A.,.. Takeda, A., Suppression of dynamin GTPase decreases alpha-synuclein uptake by neuronal and oligodendroglial cells: A potent therapeutic target for synucleinopathy. Molecular Neurodegeneration, 7, 2012, 38.
80. Kosik, K.S., Joachim, C.L., Selkoe, D.J., Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 83 (1986), 4044–4048.
81. Lee, V.M., Balin, B.J., Otvos, L. Jr., Trojanowski, J.Q., A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science 251 (1991), 675–678.
82. Lewis, J., Dickson, D.W., Propagation of tau pathology: Hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathologica 131 (2016), 27–48.
83. Lin, W.L., Dickson, D.W., Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathologica 116 (2008), 205–213.
84. Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q., Lee, V.M., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 (2012), 949–953.
85. Luk, K.C., Kehm, V.M., Zhang, B., O'Brien, P., Trojanowski, J.Q., Lee, V.M., Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. The Journal of Experimental Medicine 209 (2012), 975–986.
86. Mackenzie, I.R., Baborie, A., Pickering-Brown, S., Du Plessis, D., Jaros, E., Perry, R.H.,.. Mann, D.M., Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: Classification and relation to clinical phenotype. Acta Neuropathologica 112 (2006), 539–549.
87. Mackenzie, I.R., Neumann, M., Baborie, A., Sampathu, D.M., Du Plessis, D., Jaros, E.,.. Lee, V.M., A harmonized classification system for FTLD-TDP pathology. Acta Neuropathologica 122 (2011), 111–113.
88. Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J.,.. Higuchi, M., Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 (2013), 1094–1108.
89. Masuda, M., Suzuki, N., Taniguchi, S., Oikawa, T., Nonaka, T., Iwatsubo, T.,.. Hasegawa, M., Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45 (2006), 6085–6094.
90. Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Kubo, M., Shimozawa, A., Akiyama, H., Hasegawa, M., Pathological alpha-synuclein propagates through neural networks. Acta Neuropathologica Communications, 2, 2014, 88.
91. Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H.,.. Hasegawa, M., Prion-like spreading of pathological alpha-synuclein in brain. Brain 136 (2013), 1128–1138.
92. Masuda-Suzukake M., Shimozawa A., and Hasegawa M. Oral, intramuscular or intraperitoneal administration of alpha-synuclein fibrils did not induce phosphorylated alpha-synuclein pathologies in wild-type mouse brain. Unpublished data.
93. Matsuo, E.S., Shin, R.W., Billingsley, M.L., Van deVoorde, A., O'Connor, M., Trojanowski, J.Q., Lee, V.M., Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13 (1994), 989–1002.
94. Meng, X., Munishkina, L.A., Fink, A.L., Uversky, V.N., Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation. Biochemistry 48 (2009), 8206–8224.
95. Mirbaha, H., Holmes, B.B., Sanders, D.W., Bieschke, J., Diamond, M.I., Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. The Journal of Biological Chemistry 290 (2015), 14893–14903.
96. Miyasaka, T., Morishima-Kawashima, M., Ravid, R., Heutink, P., van Swieten, J.C., Nagashima, K., Ihara, Y., Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation. The American Journal of Pathology 158 (2001), 373–379.
97. Miyasaka, T., Morishima-Kawashima, M., Ravid, R., Kamphorst, W., Nagashima, K., Ihara, Y., Selective deposition of mutant tau in the FTDP-17 brain affected by the P301L mutation. Journal of Neuropathology and Experimental Neurology 60 (2001), 872–884.
98. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Titani, K., Ihara, Y., Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10 (1993), 1151–1160.
99. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., Ihara, Y., Proline-directed and non-proline-directed phosphorylation of PHF-tau. The Journal of Biological Chemistry 270 (1995), 823–829.
100. Mougenot, A.L., Nicot, S., Bencsik, A., Morignat, E., Verchere, J., Lakhdar, L.,.. Baron, T., Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiology of Aging 33 (2012), 2225–2228.
101. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T.,.. Lee, V.M., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006), 130–133.
102. Nielsen, T.T., Nielsen, J.E., Antisense gene silencing: Therapy for neurodegenerative disorders?. Genes (Basel) 4 (2013), 457–484.
103. Nonaka, T., Hasegawa, M., A cellular model to monitor proteasome dysfunction by alpha-synuclein. Biochemistry 48 (2009), 8014–8022.
104. Nonaka, T., Kametani, F., Arai, T., Akiyama, H., Hasegawa, M., Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Human Molecular Genetics 18 (2009), 3353–3364.
105. Nonaka, T., Masuda-Suzukake, M., Arai, T., Hasegawa, Y., Akatsu, H., Obi, T.,.. Hasegawa, M., Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Reports 4 (2013), 124–134.
106. Nonaka, T., Watanabe, S.T., Iwatsubo, T., Hasegawa, M., Seeded aggregation and toxicity of {alpha}-synuclein and tau: Cellular models of neurodegenerative diseases. The Journal of Biological Chemistry 285 (2010), 34885–34898.
107. Nukina, N., Ihara, Y., One of the antigenic determinants of paired helical filaments is related to tau protein. Journal of Biochemistry 99 (1986), 1541–1544.
108. Nuscher, B., Kamp, F., Mehnert, T., Odoy, S., Haass, C., Kahle, P.J., Beyer, K., Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: A thermodynamics study. The Journal of Biological Chemistry 279 (2004), 21966–21975.
109. Ono, K., Yamada, M., Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Journal of Neurochemistry 97 (2006), 105–115.
110. Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D.J.,.. Santarelli, L., Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Archives of Neurology 69 (2012), 198–207.
111. Paillusson, S., Clairembault, T., Biraud, M., Neunlist, M., Derkinderen, P., Activity-dependent secretion of alpha-synuclein by enteric neurons. Journal of Neurochemistry 125 (2013), 512–517.
112. Paxinou, E., Chen, Q., Weisse, M., Giasson, B.I., Norris, E.H., Rueter, S.M.,.. Ischiropoulos, H., Induction of alpha-synuclein aggregation by intracellular nitrative insult. The Journal of Neuroscience 21 (2001), 8053–8061.
113. Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M.,.. Baekelandt, V., Alpha-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522 (2015), 340–344.
114. Pooler, A.M., Phillips, E.C., Lau, D.H., Noble, W., Hanger, D.P., Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Reports 14 (2013), 389–394.
115. Prusiner, S.B., Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336 (2012), 1511–1513.
116. Prusiner, S.B., Woerman, A.L., Mordes, D.A., Watts, J.C., Rampersaud, R., Berry, D.B.,.. Giles, K., Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences of the United States of America 112 (2015), E5308–E5317.
117. Recasens, A., Dehay, B., Bove, J., Carballo-Carbajal, I., Dovero, S., Perez-Villalba, A.,.. Vila, M., Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Annals of Neurology 75 (2014), 351–362.
118. Reimann, R.R., Sonati, T., Hornemann, S., Herrmann, U.S., Arand, M., Hawke, S., Aguzzi, A., Differential toxicity of antibodies to the prion protein. PLoS Pathogens, 12, 2016, e1005401.
119. Rey, N.L., Steiner, J.A., Maroof, N., Luk, K.C., Madaj, Z., Trojanowski, J.Q.,.. Brundin, P., Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. The Journal of Experimental Medicine 213 (2016), 1759–1778.
120. Reyes, J.F., Rey, N.L., Bousset, L., Melki, R., Brundin, P., Angot, E., Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 62 (2014), 387–398.
121. Rideout, H.J., Larsen, K.E., Sulzer, D., Stefanis, L., Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. Journal of Neurochemistry 78 (2001), 899–908.
122. Rutherford, N.J., Zhang, Y.J., Baker, M., Gass, J.M., Finch, N.A., Xu, Y.F.,.. Rademakers, R., Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genetics, 4, 2008, e1000193.
123. Sacino, A.N., Brooks, M., Thomas, M.A., McKinney, A.B., Lee, S., Regenhardt, R.W.,.. Giasson, B.I., Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 111 (2014), 10732–10737.
124. Saito, Y., Kawashima, A., Ruberu, N.N., Fujiwara, H., Koyama, S., Sawabe, M.,.. Murayama, S., Accumulation of phosphorylated alpha-synuclein in aging human brain. Journal of Neuropathology and Experimental Neurology 62 (2003), 644–654.
125. Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M.,.. Bapineuzumab 201 Clinical Trial, I, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73 (2009), 2061–2070.
126. Sampathu, D.M., Neumann, M., Kwong, L.K., Chou, T.T., Micsenyi, M., Truax, A.,.. Lee, V.M., Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. The American Journal of Pathology 169 (2006), 1343–1352.
127. Sanders, D.W., Kaufman, S.K., DeVos, S.L., Sharma, A.M., Mirbaha, H., Li, A.,.. Diamond, M.I., Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82 (2014), 1271–1288.
128. Sekijima, Y., Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments. Journal of Neurology, Neurosurgery, and Psychiatry 86 (2015), 1036–1043.
129. Sekijima, Y., Tojo, K., Morita, H., Koyama, J., Ikeda, S., Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 22 (2015), 79–83.
130. Sekijima, Y., Wiseman, R.L., Matteson, J., Hammarstrom, P., Miller, S.R., Sawkar, A.R.,.. Kelly, J.W., The biological and chemical basis for tissue-selective amyloid disease. Cell 121 (2005), 73–85.
131. Serpell, L.C., Berriman, J., Jakes, R., Goedert, M., Crowther, R.A., Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proceedings of the National Academy of Sciences of the United States of America 97 (2000), 4897–4902.
132. Shimonaka, S., Nonaka, T., Suzuki, G., Hisanaga, S., Hasegawa, M., Templated aggregation of TAR DNA-binding protein of 43 kDa (TDP-43) by seeding with TDP-43 peptide fibrils. The Journal of Biological Chemistry 291 (2016), 8896–8907.
133. Sigurdsson, E.M., Tau immunotherapy. Neuro-Degenerative Diseases 16 (2016), 34–38.
134. Smethurst, P., Sidle, K.C., Hardy, J., Review: Prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). Neuropathology and Applied Neurobiology 41 (2015), 578–597.
135. Sonati, T., Reimann, R.R., Falsig, J., Baral, P.K., O'Connor, T., Hornemann, S.,.. Aguzzi, A., The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature 501 (2013), 102–106.
136. Spillantini, M.G., Crowther, R.A., Jakes, R., Cairns, N.J., Lantos, P.L., Goedert, M., Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters 251 (1998), 205–208.
137. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., Goedert, M., Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proceedings of the National Academy of Sciences of the United States of America 95 (1998), 6469–6473.
138. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
139. Sreedharan, J., Blair, I.P., Tripathi, V.B., Hu, X., Vance, C., Rogelj, B.,.. Shaw, C.E., TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319 (2008), 1668–1672.
140. Takahashi, M., Miyata, H., Kametani, F., Nonaka, T., Akiyama, H., Hisanaga, S., Hasegawa, M., Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau. Acta Neuropathologica 129 (2015), 895–907.
141. Tan, R.H., Kril, J.J., Fatima, M., McGeachie, A., McCann, H., Shepherd, C.,.. Halliday, G.M., TDP-43 proteinopathies: Pathological identification of brain regions differentiating clinical phenotypes. Brain 138 (2015), 3110–3122.
142. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., Hasegawa, M., Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. The Journal of Biological Chemistry 280 (2005), 7614–7623.
143. Taniguchi-Watanabe, S., Arai, T., Kametani, F., Nonaka, T., Masuda-Suzukake, M., Tarutani, A.,.. Hasegawa, M., Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathologica 131 (2016), 267–280.
144. Tarutani, A., Suzuki, G., Shimozawa, A., Nonaka, T., Akiyama, H., Hisanaga, S., Hasegawa, M., The effect of fragmented pathogenic alpha-synuclein seeds on prion-like propagation. The Journal of Biological Chemistry 291 (2016), 18675–18688.
145. Telling, G.C., Parchi, P., DeArmond, S.J., Cortelli, P., Montagna, P., Gabizon, R.,.. Prusiner, S.B., Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274 (1996), 2079–2082.
146. Tofaris, G.K., Razzaq, A., Ghetti, B., Lilley, K.S., Spillantini, M.G., Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. The Journal of Biological Chemistry 278 (2003), 44405–44411.
147. Tran, H.T., Chung, C.H., Iba, M., Zhang, B., Trojanowski, J.Q., Luk, K.C., Lee, V.M., Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Reports 7 (2014), 2054–2065.
148. Tsuji, H., Arai, T., Kametani, F., Nonaka, T., Yamashita, M., Suzukake, M.,.. Tamaoka, A., Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 135 (2012), 3380–3391.
149. Umeda, T., Eguchi, H., Kunori, Y., Matsumoto, Y., Taniguchi, T., Mori, H., Tomiyama, T., Passive immunotherapy of tauopathy targeting pSer413-tau: A pilot study in mice. Annals of Clinical Translational Neurology 2 (2015), 241–255.
150. Uversky, V.N., Li, J., Fink, A.L., Evidence for a partially folded intermediate in alpha-synuclein fibril formation. The Journal of Biological Chemistry 276 (2001), 10737–10744.
151. Van Deerlin, V.M., Leverenz, J.B., Bekris, L.M., Bird, T.D., Yuan, W., Elman, L.B.,.. Yu, C.E., TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis. Lancet Neurology 7 (2008), 409–416.
152. Vella, L.J., Sharples, R.A., Lawson, V.A., Masters, C.L., Cappai, R., Hill, A.F., Packaging of prions into exosomes is associated with a novel pathway of PrP processing. The Journal of Pathology 211 (2007), 582–590.
153. Villemagne, V.L., Okamura, N., Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. Current Opinion in Neurobiology 36 (2016), 43–51.
154. Watts, J.C., Giles, K., Oehler, A., Middleton, L., Dexter, D.T., Gentleman, S.M.,.. Prusiner, S.B., Transmission of multiple system atrophy prions to transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), 19555–19560.
155. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., Lansbury, P.T. Jr., NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996), 13709–13715.
156. Wood, S.J., Wypych, J., Steavenson, S., Louis, J.C., Citron, M., Biere, A.L., Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. The Journal of Biological Chemistry 274 (1999), 19509–19512.
157. Yamada, K., Holth, J.K., Liao, F., Stewart, F.R., Mahan, T.E., Jiang, H.,.. Holtzman, D.M., Neuronal activity regulates extracellular tau in vivo. The Journal of Experimental Medicine 211 (2014), 387–393.
158. Yamamoto, H., Hasegawa, M., Ono, T., Tashima, K., Ihara, Y., Miyamoto, E., Dephosphorylation of fetal-tau and paired helical filaments-tau by protein phosphatases 1 and 2A and calcineurin. Journal of Biochemistry 118 (1995), 1224–1231.
159. Yang, C., Tan, W., Whittle, C., Qiu, L., Cao, L., Akbarian, S., Xu, Z., The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PloS One, 5, 2010, e15878.
160. Yokoseki, A., Shiga, A., Tan, C.F., Tagawa, A., Kaneko, H., Koyama, A.,.. Onodera, O., TDP-43 mutation in familial amyotrophic lateral sclerosis. Annals of Neurology 63 (2008), 538–542.
161. Yonetani, M., Nonaka, T., Masuda, M., Inukai, Y., Oikawa, T., Hisanaga, S., Hasegawa, M., Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. The Journal of Biological Chemistry 284 (2009), 7940–7950.
162. Yukio, A., Yoshiki, S., Konen, O., Taro, Y., Mitsuharu, U., Yohei, M.,.. Shu-Ichi, I., Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Varl30Met: A phase III, open-label study. Journal of the Neurological Sciences 362 (2016), 266–271.
163. Zhang, X., Jin, H., Padakanti, P.K., Li, J., Yang, H., Fan, J.,.. Tu, Z., Radiosynthesis and evaluation of two PET Radioligands for imaging alpha-synuclein. Applied Sciences (Basel) 4 (2014), 66–78.